|
|
Volumn 16, Issue 3, 2008, Pages 427-428
|
|
NIH recombinant DNA advisory committee continues to ponder adverse event associated with AAV gene therapy trial
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADENOVIRUS VECTOR;
ANTIRHEUMATIC AGENT;
ETANERCEPT;
TUMOR NECROSIS FACTOR ALPHA RECEPTOR FC FUSION PROTEIN;
UNCLASSIFIED DRUG;
AUTOPSY;
BLEEDING;
CAUSE OF DEATH;
CELLULAR IMMUNITY;
EDITORIAL;
GENE TRANSFER;
HISTOPLASMOSIS;
HUMAN;
IMMUNE RESPONSE;
MEDICAL SOCIETY;
MORTALITY;
MULTIPLE ORGAN FAILURE;
RHEUMATOID ARTHRITIS;
TRANSGENE;
VIRAL GENE DELIVERY SYSTEM;
VIRAL GENE THERAPY;
|
|
EID: 39849105679
PISSN: 15250016
EISSN: 15250024
Source Type: Journal
DOI: 10.1038/mt.2008.2 Document Type: Editorial |
|
Times cited : (5)
|
|
References (1)
|
